$12B annual revenues for Lipitor the last 6-7 years of its patent life. Belviq has several applications which can spur growth here - not just one. So . . . who knows what the up side is. I have stated before that I think Belviq can approach or beat that number with worldwide distribution. Of course not all of that will fall to ARNA as we know. Still the dollars should be huge. JMO
We held Warner Lambert through the run up of Lipitor. We've now held ARNA since 2009. It may not hit the numbers of Lipitor, but even getting close will be fine with us. Thanks S. Vig!!!